This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 484 |
outcome measures | 310 |
main outcome | 281 |
care unit | 258 |
abstract type | 254 |
please specify | 254 |
ethics regulations | 238 |
mechanical ventilation | 212 |
mean age | 181 |
university hospital | 181 |
risk factors | 163 |
public health | 155 |
research abstract | 151 |
abstract background | 150 |
mg kg | 134 |
critically ill | 134 |
septic shock | 131 |
nerve conduction | 127 |
patients admitted | 122 |
author funder | 120 |
granted medrxiv | 120 |
retrospective study | 119 |
copyright holder | 117 |
version posted | 116 |
peripheral neuropathy | 115 |
years old | 113 |
mg ml | 112 |
icu admission | 111 |
health care | 110 |
clinical pharmacy | 109 |
acute respiratory | 107 |
descriptive abstract | 103 |
one patient | 101 |
side effects | 100 |
mortality rate | 100 |
care units | 99 |
infectious diseases | 97 |
clinical pharmacist | 95 |
peripheral nerve | 95 |
medication reconciliation | 94 |
least one | 93 |
two groups | 90 |
ill patients | 90 |
patients received | 90 |
made available | 89 |
study period | 88 |
nervous system | 87 |
two patients | 85 |
control group | 85 |
molecular dynamics | 84 |
significantly higher | 83 |
prospective study | 83 |
international license | 82 |
respiratory failure | 81 |
th century | 81 |
patients treated | 81 |
pharmaceutical care | 81 |
cardiac arrest | 79 |
hospital mortality | 77 |
neuropathic pain | 77 |
observational study | 77 |
respiratory distress | 77 |
median age | 76 |
adverse events | 75 |
present study | 75 |
clinical trials | 74 |
schwann cells | 74 |
cidp patients | 74 |
fatality rate | 74 |
factors associated | 73 |
staphylococcus aureus | 73 |
multivariate analysis | 71 |
blood pressure | 71 |
included patients | 71 |
inflammatory demyelinating | 70 |
significant difference | 69 |
one hundred | 65 |
medication adherence | 65 |
adult patients | 63 |
chronic inflammatory | 62 |
gbs patients | 62 |
antibiotic therapy | 62 |
drug interactions | 61 |
icu stay | 61 |
clinical practice | 60 |
results suggest | 60 |
community pharmacies | 59 |
adverse effects | 59 |
conduction studies | 58 |
peer review | 58 |
three patients | 56 |
escherichia coli | 56 |
plasma membrane | 55 |
pseudomonas aeruginosa | 55 |
per patient | 55 |
emergency department | 55 |
patients receiving | 55 |
international congresses | 54 |
internal medicine | 54 |
sofa score | 54 |
four patients | 54 |
high risk | 53 |
total number | 53 |
single molecule | 53 |
significant differences | 53 |
performed using | 52 |
lipid membranes | 52 |
membrane proteins | 52 |
logistic regression | 52 |
community pharmacy | 52 |
light scattering | 52 |
stem cells | 51 |
en france | 51 |
statistically significant | 51 |
icu patients | 51 |
two different | 50 |
clinical pharmacists | 50 |
elderly patients | 50 |
among patients | 50 |
nosocomial infections | 49 |
reproduction number | 49 |
nerve fibers | 49 |
respiratory tract | 49 |
amino acids | 48 |
related problems | 48 |
cohort study | 47 |
general population | 47 |
urinary tract | 47 |
first days | 46 |
results show | 46 |
patients hospitalized | 46 |
primary care | 46 |
renal failure | 45 |
amino acid | 45 |
axonal neuropathy | 45 |
tooth disease | 45 |
medrxiv preprint | 44 |
adverse drug | 44 |
living beings | 44 |
free energy | 44 |
atomic force | 44 |
statistical analysis | 44 |
mg dl | 44 |
lipid bilayer | 44 |
cord uid | 43 |
sex ratio | 43 |
demyelinating polyneuropathy | 43 |
electron microscopy | 43 |
pharmaceutical interventions | 43 |
independently associated | 43 |
commonly used | 43 |
patients presented | 43 |
distress syndrome | 43 |
teaching hospital | 43 |
living cells | 43 |
univariate analysis | 43 |
doc id | 43 |
lipid bilayers | 42 |
allowed us | 42 |
five patients | 42 |
risk factor | 42 |
median nerve | 42 |
important role | 42 |
cmt patients | 42 |
blood cultures | 41 |
average age | 41 |
sciatic nerve | 41 |
intravenous immunoglobulin | 41 |
severe acute | 41 |
patients without | 41 |
brain injury | 41 |
val met | 41 |
schwann cell | 41 |
health professionals | 40 |
age years | 40 |
long term | 40 |
patients included | 40 |
infected patients | 40 |
hospital stay | 40 |
community pharmacists | 39 |
eight patients | 39 |
conformational changes | 39 |
well tolerated | 39 |
lower limbs | 39 |
per day | 38 |
diabetes mellitus | 38 |
previously described | 38 |
organ failure | 38 |
data suggest | 38 |
invasive ventilation | 38 |
associated pneumonia | 38 |
susceptibility testing | 38 |
mental health | 38 |
ng ml | 37 |
infectious disease | 37 |
results obtained | 37 |
renal replacement | 37 |
immunocompromised patients | 37 |
dynamics simulations | 37 |
force microscopy | 37 |
clinical features | 37 |
kidney injury | 36 |
pilot study | 36 |
large number | 36 |
motor neuropathy | 36 |
significantly different | 36 |
inclusion criteria | 36 |
study showed | 36 |
tract infections | 36 |
fluorescence microscopy | 36 |
year period | 36 |
different types | 36 |
widely used | 36 |
experimental data | 36 |
patient safety | 36 |
replacement therapy | 36 |
confirmed cases | 36 |
medical center | 36 |
small fiber | 35 |
patient care | 35 |
circular dichroism | 35 |
significantly associated | 35 |
six patients | 35 |
poor outcome | 35 |
peripheral nervous | 35 |
blood glucose | 35 |
animal health | 35 |
high mortality | 35 |
molecular biology | 35 |
saps ii | 35 |
one case | 35 |
previous studies | 35 |
european countries | 35 |
clinical isolates | 35 |
conduction block | 34 |
clinical presentation | 34 |
primary outcome | 34 |
cancer patients | 34 |
peripheral nerves | 34 |
hospitalized patients | 34 |
drug related | 34 |
icu mortality | 34 |
first time | 34 |
klebsiella pneumoniae | 34 |
nerve injury | 33 |
significant increase | 33 |
peripheral neuropathies | 33 |
healthy controls | 33 |
gene therapy | 33 |
medical records | 33 |
streptococcus pneumoniae | 33 |
type diabetes | 33 |
gene expression | 33 |
mechanically ventilated | 33 |
fluorescent protein | 33 |
disease severity | 32 |
secondary structure | 32 |
pharmacy department | 32 |
last years | 32 |
results showed | 32 |
pg ml | 32 |
dorsal root | 32 |
muscle weakness | 32 |
coronavirus disease | 32 |
seven patients | 32 |
energy transfer | 32 |
wild type | 32 |
support scientific | 31 |
acute kidney | 31 |
viral load | 31 |
results indicate | 31 |
general hospital | 31 |
research support | 31 |
french national | 31 |
prospective observational | 31 |
data collected | 31 |
blood samples | 31 |
ntat aneo | 31 |
critical care | 31 |
prognostic factors | 31 |
case report | 31 |
scientific studies | 31 |
confocal microscopy | 31 |
drug therapy | 31 |
general practitioners | 30 |
stem cell | 30 |
mouse model | 30 |
clinical data | 30 |
significantly lower | 30 |
cell culture | 30 |
high level | 30 |
pharmacist intervention | 30 |
taste changes | 30 |
membrane protein | 30 |
tidal volume | 30 |
well known | 30 |
membrane oxygenation | 30 |
nerve biopsy | 30 |
extracorporeal membrane | 30 |
posted july | 29 |
study shows | 29 |
sural nerve | 29 |
chapter iv | 29 |
conduction velocities | 29 |
preventive approaches | 29 |
posted april | 29 |
consecutive patients | 29 |
even though | 29 |
data collection | 29 |
also observed | 29 |
clinical impact | 29 |
cerebrospinal fluid | 29 |
binding sites | 29 |
ards patients | 29 |
severe ards | 29 |
study included | 29 |
antibiotic treatment | 28 |
cardiogenic shock | 28 |
tract infection | 28 |
analysis showed | 28 |
poor prognosis | 28 |
including patients | 28 |
hospital pharmacy | 28 |
antibiotic resistance | 28 |
increased risk | 28 |
french government | 28 |
cell lines | 28 |
wide range | 28 |
demyelinating neuropathy | 28 |
previously reported | 28 |
world health | 28 |
study aimed | 28 |
electron transfer | 28 |
health organization | 28 |
medication review | 28 |
skin biopsy | 28 |
viral rna | 28 |
disease progression | 28 |
sh tc | 28 |
took place | 27 |
may help | 27 |
plasma exchange | 27 |
hcv genotype | 27 |
experimental method | 27 |
rights reserved | 27 |
posted may | 27 |
without permission | 27 |
patients diagnosed | 27 |
nursing home | 27 |
median time | 27 |
medical care | 27 |
study conducted | 27 |
study group | 27 |
axonal degeneration | 27 |
fluorescence spectroscopy | 27 |
clinical characteristics | 27 |
reuse allowed | 27 |
immune response | 27 |
ml kg | 27 |
medical school | 27 |
enteral nutrition | 27 |
pediatric intensive | 27 |
steady state | 27 |
antimicrobial resistance | 27 |
allowed without | 27 |
sensory neurons | 27 |
ventilated patients | 27 |
per year | 27 |
autosomal dominant | 26 |
renal function | 26 |
hev strains | 26 |
heart failure | 26 |
significantly increased | 26 |
time series | 26 |
clinically relevant | 26 |
nerve fiber | 26 |
bone marrow | 26 |
type i | 26 |
hcv rna | 26 |
amyloid fibrils | 26 |
gbs disability | 26 |
united states | 26 |
standard deviation | 26 |
resistant strains | 26 |
veterinary medicine | 26 |
correlation spectroscopy | 26 |
first step | 26 |
lower limb | 26 |
real time | 26 |
agar dilution | 26 |
th day | 26 |
molecular mechanisms | 26 |
multidisciplinary team | 25 |
ffi ffi | 25 |
march th | 25 |
clavulanic acid | 25 |
diabetic neuropathy | 25 |
health system | 25 |
linear regression | 25 |
mortality rates | 25 |
pao fio | 25 |
medical icu | 25 |
diaphragm dysfunction | 25 |
significant decrease | 25 |
ml min | 25 |
cell membranes | 25 |
protein folding | 25 |
extubation failure | 25 |
nucleic acids | 25 |
hospital admission | 25 |
healthy subjects | 25 |
flow cytometry | 25 |
resistant bacteria | 25 |
skin biopsies | 25 |
united kingdom | 25 |
family members | 25 |
sensory neuropathy | 25 |
cardiac surgery | 25 |
patients using | 25 |
central nervous | 25 |
active site | 24 |
drg neurons | 24 |
serum creatinine | 24 |
conduction velocity | 24 |
hospital discharge | 24 |
respiratory syndrome | 24 |
better understand | 24 |
healthcare professionals | 24 |
national institute | 24 |
preliminary results | 24 |
two weeks | 24 |
life sciences | 24 |
antimicrobial susceptibility | 24 |
novel coronavirus | 24 |
outer membrane | 24 |
patients aged | 24 |
clinical signs | 24 |
odds ratio | 24 |
conduction study | 24 |
pharmacy service | 24 |
dose adjustment | 24 |
binding site | 24 |
predictive value | 24 |
sensory loss | 24 |
two types | 24 |
body weight | 24 |
systematic review | 24 |
cell death | 24 |
drug resistance | 24 |
model system | 24 |
invasive mechanical | 24 |
bacterial infection | 24 |
heart rate | 24 |
parenteral nutrition | 24 |
nine patients | 24 |
demyelinating polyradiculoneuropathy | 24 |
two cases | 23 |
psychiatric hospitals | 23 |
patients compared | 23 |
blood culture | 23 |
sensory nerve | 23 |
old man | 23 |
may lead | 23 |
patients underwent | 23 |
diffusion method | 23 |
dialysis patients | 23 |
peripheral blood | 23 |
carpal tunnel | 23 |
drug reactions | 23 |
healthcare system | 23 |
symptomatic cases | 23 |
acute renal | 23 |
protective effect | 23 |
medical history | 23 |
collected data | 23 |
en milieu | 23 |
action potential | 23 |
disability score | 23 |
nerve regeneration | 23 |
myelin protein | 23 |
control measures | 23 |
dilution method | 23 |
protein interactions | 23 |
acute phase | 23 |
prone position | 23 |
one week | 23 |
neurological examination | 23 |
first line | 23 |
blood flow | 23 |
three different | 23 |
one year | 23 |
study including | 23 |
determine whether | 23 |
kg day | 22 |
findings suggest | 22 |
fluorescence lifetime | 22 |
structural changes | 22 |
allows us | 22 |
month period | 22 |
heart disease | 22 |
fluorescent proteins | 22 |
hospital pharmacists | 22 |
unilamellar vesicles | 22 |
confidence interval | 22 |
ligand binding | 22 |
high dose | 22 |
pulmonary disease | 22 |
six months | 22 |
bactericidal activity | 22 |
cd cd | 22 |
may also | 22 |
antibiotic use | 22 |
slowly progressive | 22 |
determined using | 22 |
loading dose | 22 |
fluid responsiveness | 22 |
clinical response | 22 |
mean duration | 22 |
negatively charged | 22 |
antimicrobial agents | 22 |
traumatic brain | 22 |
diffusion process | 22 |
significant association | 22 |
rabbit hev | 22 |
data show | 22 |
acquired pneumonia | 22 |
blood cells | 22 |
psychiatric care | 22 |
france please | 22 |
retrospective analysis | 22 |
fatality rates | 22 |
publique france | 22 |
niv failure | 22 |
cell biology | 22 |
root ganglia | 22 |
cell membrane | 22 |
remote systems | 22 |
severe sepsis | 22 |
distal leg | 21 |
medical microbiology | 21 |
present work | 21 |
ischemic stroke | 21 |
pharmacy services | 21 |
ion channels | 21 |
will provide | 21 |
care professionals | 21 |
early onset | 21 |
es cells | 21 |
diagnostic criteria | 21 |
sum score | 21 |
magnetic resonance | 21 |
patients presenting | 21 |
recent years | 21 |
kidney disease | 21 |
chronic obstructive | 21 |
retrospective observational | 21 |
highly conserved | 21 |
clinical relevance | 21 |
drug delivery | 21 |
patients reported | 21 |
analyzed using | 21 |
medication errors | 21 |
time points | 21 |
results will | 21 |
ii score | 21 |
vitro activity | 21 |
one month | 21 |
motor axonal | 21 |
strains isolated | 21 |
disk diffusion | 21 |
critical illness | 21 |
health authorities | 21 |
cell line | 21 |
copies ml | 21 |
key role | 21 |
reactive protein | 21 |
french population | 20 |
motor nerve | 20 |
higher risk | 20 |
medication reviews | 20 |
sciatic nerves | 20 |
cirrhotic patients | 20 |
igg antibodies | 20 |
similar results | 20 |
significantly reduced | 20 |
porcine epidemic | 20 |
clinical improvement | 20 |
france correspondence | 20 |
diabetic patients | 20 |
patients developed | 20 |
ivig treatment | 20 |
cell surface | 20 |
remaining patients | 20 |
status epilepticus | 20 |
neurological outcome | 20 |
taken together | 20 |
mic mg | 20 |
health workers | 20 |
transmission rate | 20 |
general practitioner | 20 |
intervention group | 20 |
two main | 20 |
acute exacerbation | 20 |
mrc sum | 20 |
intracranial hypertension | 20 |
french addictovigilance | 20 |
one hand | 20 |
distal motor | 20 |
leading cause | 20 |
axonal loss | 20 |
protein structure | 20 |
clinical trial | 20 |
first week | 20 |
within days | 20 |
metropolitan france | 19 |
treated patients | 19 |
des mesures | 19 |
ct scan | 19 |
clinical phenotype | 19 |
high morbidity | 19 |
igg anti | 19 |
primary objective | 19 |
ibd patients | 19 |
patients infected | 19 |
long time | 19 |
regression analysis | 19 |
animal models | 19 |
epidermal nerve | 19 |
grip strength | 19 |
icu discharge | 19 |
disease duration | 19 |
frequently used | 19 |
line treatment | 19 |
medication discrepancies | 19 |
treatment response | 19 |
early diagnosis | 19 |
antibiotic prophylaxis | 19 |
gives rise | 19 |
central venous | 19 |
antibiotic susceptibility | 19 |
literature review | 19 |
mechanical properties | 19 |
body mass | 19 |
red blood | 19 |
fluorescence intensity | 19 |
exclusion criteria | 19 |
dynamic light | 19 |
upper respiratory | 19 |
control study | 19 |
regression model | 19 |
old woman | 19 |
clinical symptoms | 19 |
reverse transcription | 19 |
year old | 19 |
cryptosporidium species | 19 |
patients suffering | 19 |
skeletal muscle | 19 |
binding proteins | 19 |
resistance rates | 19 |
base pairs | 19 |
predictive factors | 19 |
exome sequencing | 19 |
autonomic dysfunction | 19 |
clinical examination | 19 |
two hundred | 19 |
liver transplantation | 19 |
ulnar nerve | 19 |
dipartimento di | 18 |
differential equations | 18 |
chronic diseases | 18 |
patients undergoing | 18 |
istituto di | 18 |
posted june | 18 |
high rate | 18 |
hiv infection | 18 |
studies showed | 18 |
molecular level | 18 |
lipid membrane | 18 |
neuropathy score | 18 |
rna replication | 18 |
healthy volunteers | 18 |
infected individuals | 18 |
multiple sclerosis | 18 |
three cases | 18 |
ethics committee | 18 |
median duration | 18 |
interfering rnas | 18 |
current study | 18 |
infectious complications | 18 |
economic model | 18 |
binding protein | 18 |
smell taste | 18 |
informed consent | 18 |
acinetobacter baumannii | 18 |
type ii | 18 |
motor neurons | 18 |
allow us | 18 |
fatty acids | 18 |
drug use | 18 |
genetic engineering | 18 |
signi cant | 18 |
flow nasal | 18 |
secondary outcomes | 18 |
obstructive pulmonary | 18 |
spinal cord | 18 |
symptom onset | 18 |
age classes | 18 |
higher mortality | 18 |
broad spectrum | 18 |
blood cell | 17 |
antimicrobial peptides | 17 |
circulatory failure | 17 |
investigate whether | 17 |
hcv treatment | 17 |
neutropenic patients | 17 |
wild rabbits | 17 |
live cells | 17 |
mass index | 17 |
industrial vets | 17 |
pharmaceutical analysis | 17 |
university medical | 17 |
clinically significant | 17 |
wallerian degeneration | 17 |
protein complexes | 17 |
compassionate use | 17 |
clostridium difficile | 17 |
creatinine clearance | 17 |
burn patients | 17 |
also found | 17 |
controlled trial | 17 |
average duration | 17 |
multidrug resistance | 17 |
graduate school | 17 |
three months | 17 |
response rate | 17 |
data obtained | 17 |
operating room | 17 |
remote clinics | 17 |
fundamental research | 17 |
inflammatory response | 17 |
veterinary profession | 17 |
mean number | 17 |
outcome measure | 17 |
medical devices | 17 |
day mortality | 17 |
south korea | 17 |
better understanding | 17 |
tunnel syndrome | 17 |
research center | 17 |
media coverage | 17 |
sectional study | 17 |
biological systems | 17 |
patients required | 17 |
messenger rna | 17 |
dans les | 17 |
different time | 17 |
clinical course | 17 |
renal impairment | 17 |
chapter iii | 17 |
high doses | 17 |
pharmacy students | 17 |
negative bacteria | 17 |
pharmacy practice | 17 |
therapeutic management | 17 |
breast cancer | 17 |
data regarding | 17 |
cancer cells | 17 |
significant improvement | 17 |
otitis media | 17 |
atrial fibrillation | 17 |
candida species | 17 |
prospective cohort | 17 |
epidemic diarrhea | 17 |
inhibitory concentration | 17 |
arterial blood | 17 |
patients showed | 17 |
drug resistant | 17 |
professional expertise | 17 |
assessed using | 17 |
molecule fluorescence | 17 |
pressure support | 16 |
ray scattering | 16 |
medical university | 16 |
drug monitoring | 16 |
age class | 16 |
asylum facilities | 16 |
clinical outcomes | 16 |
family history | 16 |
mg day | 16 |
average number | 16 |
oxygen therapy | 16 |
resistant staphylococcus | 16 |
using different | 16 |
johns hopkins | 16 |
required mechanical | 16 |
maladies infectieuses | 16 |
upper limbs | 16 |
russian federation | 16 |
mitochondrial trafficking | 16 |
significantly decreased | 16 |
onset vap | 16 |
clin pharm | 16 |
fluorescence correlation | 16 |
physical chemistry | 16 |
intravenous immunoglobulins | 16 |
antibiotic prescription | 16 |
action potentials | 16 |
social distancing | 16 |
independent risk | 16 |
results patients | 16 |
model membranes | 16 |
nosocomial infection | 16 |
high resolution | 16 |
esophageal pressure | 16 |
may contribute | 16 |
icu length | 16 |
transition period | 16 |
fiber density | 16 |
several studies | 16 |
induced peripheral | 16 |
pulmonary embolism | 16 |
acid residues | 16 |
retrospective cohort | 16 |
chain length | 16 |
foot drop | 16 |
medical staff | 16 |
model systems | 16 |
major cause | 16 |
data analysis | 16 |
confocal laser | 16 |
terminal domain | 16 |
photosystem ii | 16 |
mouse models | 16 |
antiretroviral therapy | 16 |
months later | 16 |
ex vivo | 16 |
remains unclear | 16 |
across regions | 16 |
study aims | 16 |
positive patients | 16 |
laser scanning | 16 |
oral chemotherapy | 16 |
containment measures | 16 |
lower respiratory | 16 |
closely related | 16 |
cell cycle | 15 |
combination therapy | 15 |
age group | 15 |
least two | 15 |
fiber neuropathy | 15 |
muscle strength | 15 |
children aged | 15 |
prone positioning | 15 |
spontaneous breathing | 15 |
clinical parameters | 15 |
first one | 15 |
fungal infections | 15 |
cell transplantation | 15 |
medical record | 15 |
mental illness | 15 |
oral anticoagulants | 15 |
mag neuropathy | 15 |
genetic correlations | 15 |
may result | 15 |
biophysical chemistry | 15 |
patients died | 15 |
assistance publique | 15 |
invasive aspergillosis | 15 |
june th | 15 |
france background | 15 |
old male | 15 |
will allow | 15 |
state university | 15 |
high prevalence | 15 |
case fatality | 15 |
reverse transcriptase | 15 |
nursing staff | 15 |
incidence rate | 15 |
positive impact | 15 |
social media | 15 |
hbv dna | 15 |
minimum inhibitory | 15 |
green fluorescent | 15 |
oxidative stress | 15 |
crystal structure | 15 |
double helix | 15 |
white blood | 15 |
online teaching | 15 |
ganglioside antibodies | 15 |
herbal products | 15 |
virus infection | 15 |
therapeutic strategies | 15 |
therapeutic cloning | 15 |
intraepidermal nerve | 15 |
data indicate | 15 |
nucleic acid | 15 |
drug information | 15 |
immune responses | 15 |
treatment duration | 15 |
severity score | 15 |
membrane potential | 15 |
cell count | 15 |
gel electrophoresis | 15 |
csl behring | 15 |
care service | 15 |
prognostic value | 15 |
college london | 15 |
spatial diffusion | 15 |
culture medium | 15 |
addictovigilance network | 15 |
medical treatment | 15 |
daily basis | 15 |
pharmaceutical validation | 15 |
clinical strains | 15 |
pmp gene | 15 |
cardiovascular disease | 15 |
study highlights | 15 |
inherited peripheral | 15 |
research institute | 15 |
may explain | 15 |
conformational change | 15 |
main objective | 15 |
conducted using | 15 |
line therapy | 15 |
neuropathy patients | 15 |
severely affected | 14 |
healthcare use | 14 |
potentially inappropriate | 14 |
outpatient clinic | 14 |
pregnant women | 14 |
economic impact | 14 |
main reason | 14 |
fat diet | 14 |
also showed | 14 |
descriptive study | 14 |
gene delivery | 14 |
randomized controlled | 14 |
dependent manner | 14 |
conclusion reached | 14 |
poorly understood | 14 |
total cholesterol | 14 |
million people | 14 |
lymphocyte proliferation | 14 |
transplant recipients | 14 |
hereditary neuropathy | 14 |
standard care | 14 |
total population | 14 |
expiratory pressure | 14 |
th centuries | 14 |
different countries | 14 |
patient received | 14 |
will present | 14 |
peripheral myelin | 14 |
observational cohort | 14 |
medical research | 14 |
orthopaedic surgery | 14 |
demographic data | 14 |
acute pancreatitis | 14 |
sensory ataxia | 14 |
patient presented | 14 |
eye drops | 14 |
raman spectroscopy | 14 |
psychoactive substances | 14 |
french hospitals | 14 |
prescribed drugs | 14 |
evaluated using | 14 |
lumbar puncture | 14 |
en charge | 14 |
cell adhesion | 14 |
animal model | 14 |
reproductive cloning | 14 |
identify factors | 14 |
immunodeficiency virus | 14 |
health services | 14 |
endoplasmic reticulum | 14 |
biological membranes | 14 |
septic patients | 14 |
charcot marie | 14 |
arterial pressure | 14 |
nasal cannula | 14 |
first study | 14 |
plasma concentrations | 14 |
murine typhus | 14 |
autosomal recessive | 14 |
resonance imaging | 14 |
french society | 14 |
therapeutic drug | 14 |
fibers mm | 14 |
serum concentration | 14 |
chain reaction | 14 |
polymerase chain | 14 |
patient education | 14 |
two years | 14 |
lipid composition | 14 |
copd patients | 14 |
new york | 14 |
inflammatory neuropathies | 14 |
weaning failure | 14 |
medication history | 14 |
sensory symptoms | 14 |
monocentric study | 14 |
motor conduction | 14 |
medication knowledge | 14 |
weight loss | 14 |
recent studies | 14 |
nitric oxide | 14 |
mobile phone | 14 |
hacettepe university | 14 |
tertiary hospital | 14 |
mag antibodies | 14 |
folic acid | 14 |
measured using | 14 |
primary endpoint | 14 |
fio ratio | 14 |
marie tooth | 14 |
italian institute | 14 |
icu beds | 13 |
refractory cardiac | 13 |
messenger rnas | 13 |
year follow | 13 |
myelin sheath | 13 |
analysis revealed | 13 |
infected cells | 13 |
endotracheal tube | 13 |
continental france | 13 |
adaptive immunity | 13 |
still unclear | 13 |
sensory testing | 13 |
one day | 13 |
control patients | 13 |
common cause | 13 |
new therapeutic | 13 |
negative bacilli | 13 |
hev genotypes | 13 |
patient counselling | 13 |
stopp criteria | 13 |
early detection | 13 |
adverse event | 13 |
coli strains | 13 |
ill children | 13 |
atpase activity | 13 |
cystic fibrosis | 13 |
study population | 13 |
multifocal motor | 13 |
des maladies | 13 |
extended spectrum | 13 |
increased mortality | 13 |
spectrum beta | 13 |
experiments carried | 13 |
experimental results | 13 |
trauma patients | 13 |
drug treatment | 13 |
missense mutations | 13 |
lung injury | 13 |
infected cases | 13 |
medical intensive | 13 |
normal values | 13 |
hospital setting | 13 |
shock patients | 13 |
early stage | 13 |
embryonic stem | 13 |
study provides | 13 |
proper use | 13 |
tertiary care | 13 |
acute brain | 13 |
sur le | 13 |
genetically modified | 13 |
direct examination | 13 |
amr problem | 13 |
farmed rabbits | 13 |
lockdown period | 13 |
neutron scattering | 13 |
placebo group | 13 |
ten patients | 13 |
glasgow coma | 13 |
force spectroscopy | 13 |
frequently reported | 13 |
hoc analysis | 13 |
en place | 13 |
serum concentrations | 13 |
studied using | 13 |
clinical outcome | 13 |
first two | 13 |
protein aggregation | 13 |
clinical studies | 13 |
fibril formation | 13 |
protein aggregates | 13 |
differential diagnosis | 13 |
initial number | 13 |
rna interference | 13 |
medical sciences | 13 |
clinical efficacy | 13 |
rheumatoid arthritis | 13 |
cytokine production | 13 |
acquired weakness | 13 |
potassium channels | 13 |
patients requiring | 13 |
myocardial infarction | 13 |
median number | 13 |
study performed | 13 |
analysed using | 13 |
transmission dynamics | 13 |
di fisica | 13 |
emergency room | 13 |
year survival | 13 |
aggregated hospital | 13 |
human strain | 13 |
sectional area | 13 |
patients consulting | 13 |
optical tweezers | 13 |
analysis using | 13 |
contagious people | 13 |
days later | 13 |
underlying disease | 13 |
results support | 13 |
prescription drugs | 13 |
ionic strength | 13 |
pmp duplication | 13 |
infected people | 13 |
respiratory rate | 13 |
serious adverse | 13 |
motor neuron | 13 |
pk pd | 13 |
takes place | 13 |
pharmaceutical services | 13 |
french public | 13 |
risk patients | 13 |
patients may | 13 |
will help | 13 |
disease onset | 13 |
inhibitory effect | 13 |
neuroscience institute | 13 |
posted august | 13 |
stenotrophomonas maltophilia | 13 |
immune cells | 13 |
surface area | 13 |
hereditary neuropathies | 13 |
eukaryotic cells | 13 |
bloodstream infections | 13 |
patch clamp | 13 |
platelet count | 13 |
french regions | 13 |
seir model | 13 |
neurological disorders | 13 |
apache ii | 12 |
fluorescently labeled | 12 |
university hospitals | 12 |
lunatic asylum | 12 |
high affinity | 12 |
following data | 12 |
brachial plexus | 12 |
also performed | 12 |
two proteins | 12 |
supportive care | 12 |
inherited neuropathy | 12 |
liver failure | 12 |
sodium channel | 12 |
immune system | 12 |
twelve patients | 12 |
beneficial effect | 12 |
low adherence | 12 |
qualitative study | 12 |
preliminary data | 12 |
bacterial infections | 12 |
pulmonary edema | 12 |
glycaemic control | 12 |
inflammatory neuropathy | 12 |
efns pns | 12 |
cellular processes | 12 |
prospective studies | 12 |
using fluorescence | 12 |
paris france | 12 |
effective reproduction | 12 |
i will | 12 |
incubation period | 12 |
gm antibody | 12 |
previous treatment | 12 |
control groups | 12 |
motor axons | 12 |
tissue sections | 12 |
structural properties | 12 |
control subjects | 12 |
mesenteric ischemia | 12 |
hospital admissions | 12 |
axonal transport | 12 |
acute inflammatory | 12 |
fluorescent molecules | 12 |
patients will | 12 |
suspect cases | 12 |
daily dose | 12 |
large scale | 12 |
significant correlation | 12 |
urban centres | 12 |
urine samples | 12 |
chest wall | 12 |
diarrhea virus | 12 |
cox model | 12 |
fully understood | 12 |
medication lists | 12 |
chronic pain | 12 |
nccls guidelines | 12 |
last months | 12 |
patient developed | 12 |
small interfering | 12 |
unfolded state | 12 |
scanning microscopy | 12 |
liver transplant | 12 |
health crisis | 12 |
thirty patients | 12 |
cmt genes | 12 |
antifungal agents | 12 |
aged years | 12 |
negative predictive | 12 |
secondary objective | 12 |
sanger sequencing | 12 |
national university | 12 |
ppis prescriptions | 12 |
effective treatment | 12 |
experimental conditions | 12 |
cd cells | 12 |
hev rna | 12 |
selection bias | 12 |
dosage regimen | 12 |
acinetobacter baumanii | 12 |
future studies | 12 |
mass spectrometry | 12 |
molecular weight | 12 |
viral replication | 12 |
significant impact | 12 |
chronic hepatitis | 12 |
significant reduction | 12 |
crystal structures | 12 |
pharmacist interventions | 12 |
classified according | 12 |
molecular motors | 12 |
high incidence | 12 |
acceptance rate | 12 |
last decades | 12 |
nerve crush | 12 |
broad range | 12 |
care patients | 12 |
gold standard | 12 |
adverse effect | 12 |
mainland france | 12 |
room temperature | 12 |
also studied | 12 |
neuromuscular diseases | 12 |
infectious cases | 12 |
resonance energy | 12 |
viral infection | 12 |
weaning protocol | 12 |
respiratory system | 12 |
patients years | 12 |
hopkins university | 12 |
early stages | 12 |
monte carlo | 12 |
water molecules | 12 |
hereditary motor | 12 |
developing countries | 12 |
typical cidp | 12 |
des personnes | 12 |
zika virus | 12 |
medication use | 12 |
physical properties | 12 |
single center | 12 |
dna sequence | 12 |
age groups | 12 |
livestock farming | 12 |
nerve excitability | 12 |
influenza patients | 12 |
may th | 12 |
czech republic | 12 |
center study | 12 |
poultry vets | 12 |
live cell | 12 |
ef ciency | 12 |
overall mortality | 12 |
physiological conditions | 12 |
molecular interactions | 12 |
hemoglobin level | 12 |
improve patient | 12 |
fungal infection | 12 |
small number | 12 |
pharmaceutical industry | 12 |
well plates | 11 |
small size | 11 |
generation sequencing | 11 |
pharmacist notes | 11 |
university school | 11 |
higher proportion | 11 |
model parameters | 11 |
lockdown measures | 11 |
experimental study | 11 |
purulent discharge | 11 |
hospitalized cases | 11 |
times higher | 11 |
quantitative sensory | 11 |
resistant isolates | 11 |
multivariate regression | 11 |
first group | 11 |
older age | 11 |
optical properties | 11 |
directly related | 11 |
life support | 11 |
reactive oxygen | 11 |
risk assessment | 11 |
less frequently | 11 |
novel approach | 11 |
regional level | 11 |
disease activity | 11 |
diabetic peripheral | 11 |
nf antibodies | 11 |
surgical site | 11 |
least days | 11 |
every day | 11 |
protein dynamics | 11 |
medical department | 11 |
reference strain | 11 |
eligible patients | 11 |
pour les | 11 |
many countries | 11 |
tooth neuropathy | 11 |
financial support | 11 |
gbs outcome | 11 |
mean value | 11 |
groups according | 11 |
brain mri | 11 |
surface charge | 11 |
online survey | 11 |
systolic function | 11 |
whole exome | 11 |
nf antibody | 11 |
bariatric surgery | 11 |
myasthenia gravis | 11 |
french university | 11 |
high levels | 11 |
therapeutic strategy | 11 |
ventilator associated | 11 |
steroidal anti | 11 |
bacterial meningitis | 11 |
comparative study | 11 |
foot deformities | 11 |
chronic kidney | 11 |
general anesthesia | 11 |
second step | 11 |
mutant mice | 11 |
prognostic impact | 11 |
new infections | 11 |
mental disorders | 11 |
cell imaging | 11 |
clinical microbiology | 11 |
oxygen species | 11 |
lipid vesicles | 11 |
regional hospital | 11 |
af nity | 11 |
md simulations | 11 |
chronic hcv | 11 |
titration calorimetry | 11 |
health promotion | 11 |
focus group | 11 |
actin filaments | 11 |
susceptible strains | 11 |
soins psychiatriques | 11 |
therapeutic range | 11 |
state nmr | 11 |
preliminary study | 11 |
requiring mechanical | 11 |
cell division | 11 |
gram negative | 11 |
host cell | 11 |
significant changes | 11 |
frequent cause | 11 |
single molecules | 11 |
primary health | 11 |
disease type | 11 |
specific antibodies | 11 |
resistant cell | 11 |
experiments showed | 11 |
secondary objectives | 11 |
hospital care | 11 |
severe infections | 11 |
clinical severity | 11 |
findings indicate | 11 |
adverse reactions | 11 |
growth factor | 11 |
mean time | 11 |
organ dysfunction | 11 |
initial treatment | 11 |
buenos aires | 11 |
cardiac index | 11 |
signi cantly | 11 |
average time | 11 |
support ventilation | 11 |
confidence intervals | 11 |
three times | 11 |
dans le | 11 |
di biofisica | 11 |
two distinct | 11 |
acute hepatitis | 11 |
average length | 11 |
results demonstrate | 11 |
six cases | 11 |
study confirms | 11 |
reported cases | 11 |
post hoc | 11 |
cells transfected | 11 |
hcv replicon | 11 |
high flow | 11 |
led us | 11 |
increased significantly | 11 |
using two | 11 |
exit strategies | 11 |
phase transition | 11 |
severity scores | 11 |
reproductive number | 11 |
human immunodeficiency | 11 |
least three | 11 |
mrc grade | 11 |
soft tissue | 11 |
mait cells | 11 |
sunlight exposure | 11 |
continuous infusion | 11 |
lung cancer | 11 |
respiratory infections | 11 |
patients experienced | 11 |
late onset | 11 |
results confirm | 11 |
results provide | 11 |
paediatric patients | 11 |
may influence | 11 |
electrostatic interactions | 11 |
viral infections | 11 |
statistical significance | 11 |
showed significant | 11 |
policy measures | 11 |
confirmed covid | 11 |
nk cells | 11 |
clinical diagnosis | 11 |
islamic republic | 11 |
unfavorable outcome | 11 |
clinical hospital | 11 |
motor axon | 11 |
make use | 11 |
twice daily | 11 |
nk cell | 11 |
cell clones | 11 |
inflammatory drugs | 11 |
heritability estimates | 11 |
experimental medicine | 11 |
pain threshold | 11 |
excited state | 11 |
studies show | 11 |
national neuroscience | 11 |
study will | 11 |
infection rate | 11 |
proton pump | 11 |
inflammatory cytokines | 11 |
connective tissue | 11 |
cell types | 11 |
significant effect | 11 |
liver cirrhosis | 11 |
baseline characteristics | 11 |
surveillance system | 11 |
patients enrolled | 11 |
also known | 11 |
laboratory tests | 11 |
domain iii | 11 |
community pharmacist | 11 |
new method | 11 |
noninvasive ventilation | 11 |
painful neuropathy | 11 |
aire gw | 11 |
protein unfolding | 10 |
examination showed | 10 |
isothermal titration | 10 |
antibacterial activity | 10 |
cell activity | 10 |
preventive measures | 10 |
auc mic | 10 |
study design | 10 |
rank test | 10 |
planck institute | 10 |
brain barrier | 10 |
medical faculty | 10 |
human medicine | 10 |
time scale | 10 |
haemophilus influenzae | 10 |
membrane tension | 10 |
first day | 10 |
monoclonal antibodies | 10 |
icu organisation | 10 |
basic protein | 10 |
hydration water | 10 |
time resolved | 10 |
liver disease | 10 |
light chain | 10 |
epidemic model | 10 |
fisher syndrome | 10 |
enteral feeding | 10 |
total patients | 10 |
clinical case | 10 |
good clinical | 10 |
cmt neuropathy | 10 |
prospectively collected | 10 |
isolated bacteria | 10 |
received mg | 10 |
containment policies | 10 |
patient information | 10 |
relatively high | 10 |
aggregation process | 10 |
literature search | 10 |
drug events | 10 |
motor symptoms | 10 |
ray crystallography | 10 |
high resistance | 10 |
mammalian cells | 10 |
membrane surface | 10 |
normal controls | 10 |
breathing trial | 10 |
public hospitals | 10 |
early phase | 10 |
medical information | 10 |
phase separation | 10 |
human genome | 10 |
acquired infections | 10 |
psychiatriques en | 10 |
high frequency | 10 |
antibiotic prescriptions | 10 |
small angle | 10 |
exponential growth | 10 |
also used | 10 |
lateral sclerosis | 10 |
tyrosine kinase | 10 |
patients tested | 10 |
antibody response | 10 |
positive predictive | 10 |
antimicrobial therapy | 10 |
human mobility | 10 |
molecular mechanism | 10 |
cancer cell | 10 |
pandemic transmission | 10 |
applied biosystems | 10 |
first part | 10 |
recently reported | 10 |
structural information | 10 |
patients also | 10 |
walk independently | 10 |
candida albicans | 10 |
drug sales | 10 |
simulated patient | 10 |
tissue concentration | 10 |
fatality ratio | 10 |
next generation | 10 |
amyotrophic lateral | 10 |
hepatic encephalopathy | 10 |
pancreatic carcinoma | 10 |
plexus mri | 10 |
acute mesenteric | 10 |
temperature range | 10 |
satisfaction survey | 10 |
institut pasteur | 10 |
fresenius medical | 10 |
neurite outgrowth | 10 |
distal thigh | 10 |
optical microscopy | 10 |
arterial hypertension | 10 |
years later | 10 |
left ventricular | 10 |
antisense strand | 10 |
success rate | 10 |
hcv infection | 10 |
piperacillin tazobactam | 10 |
cfu ml | 10 |
lifetime imaging | 10 |
lower extremity | 10 |
ab vap | 10 |
vast majority | 10 |
much higher | 10 |
one patients | 10 |
ulcerative colitis | 10 |
new south | 10 |
sample preparation | 10 |
longitudinal study | 10 |
patient died | 10 |
older adults | 10 |
innate immunity | 10 |
health insurance | 10 |
spectrum antibiotics | 10 |
ace inhibitors | 10 |
health emergency | 10 |
years ago | 10 |
sensitivity analysis | 10 |
mechanisms involved | 10 |
time spent | 10 |
also considered | 10 |
polymedicated patients | 10 |
vasoactive drugs | 10 |
airway pressure | 10 |
two methods | 10 |
mathematical model | 10 |
giant unilamellar | 10 |
current treatment | 10 |
early treatment | 10 |
evaluate whether | 10 |
pns criteria | 10 |
studies will | 10 |
possible role | 10 |
innovation diffusion | 10 |
quality control | 10 |
channel activity | 10 |
developed vap | 10 |
ion channel | 10 |
genetic code | 10 |
categorical variables | 10 |
positive culture | 10 |
national level | 10 |
chronic respiratory | 10 |
good agreement | 10 |
sur les | 10 |
take place | 10 |
multicenter study | 10 |
single dose | 10 |
admitted patients | 10 |
new cases | 10 |
nerve function | 10 |
remote work | 10 |
dry cough | 10 |
physical activity | 10 |
one third | 10 |
polypeptide chain | 10 |
tooth type | 10 |
national government | 10 |
modelling study | 10 |
positive cidp | 10 |
hypercapnic respiratory | 10 |
genetic heterogeneity | 10 |
significantly correlated | 10 |
health problem | 10 |
french authorities | 10 |
signal transduction | 10 |
therapeutic targets | 10 |
hematological malignancies | 10 |
mechanisms leading | 10 |
cancer treatment | 10 |
hip fracture | 10 |
binding domain | 10 |
formulary drugs | 10 |
within weeks | 10 |
injury severity | 10 |
days following | 10 |
medication information | 10 |
le risque | 10 |
diagnostic accuracy | 10 |
supine position | 10 |
transcription factor | 10 |
per week | 10 |
nerve damage | 10 |
main causes | 10 |
french ministry | 10 |
maximum likelihood | 10 |
iowa city | 10 |
pneumoniae isolates | 10 |
inherited neuropathies | 10 |
spatial distribution | 10 |
patient interview | 10 |
cell lymphoma | 10 |
sensory axons | 10 |
hospitalization rate | 10 |
case series | 10 |
therapeutic effect | 10 |
nerve degeneration | 10 |
protein levels | 10 |
atp synthase | 10 |
local signs | 10 |
prise en | 10 |
affected patients | 10 |
median length | 10 |
new drugs | 10 |
press release | 10 |
nerve ultrasound | 10 |
common complication | 10 |
molecule level | 10 |
potential role | 10 |
acute motor | 10 |
photon excitation | 10 |
somatic cell | 10 |
chu angers | 10 |
viral hepatitis | 10 |
endothelial cells | 10 |
poor response | 10 |
blood agar | 10 |
second ivig | 10 |
group compared | 10 |
antifungal therapy | 10 |
primary end | 10 |
neurology department | 10 |
dm patients | 10 |
randomly assigned | 10 |
methicillin resistant | 10 |
disease course | 10 |
niv hfnc | 10 |
healthcare systems | 10 |
hierarchical diffusion | 10 |
second one | 10 |
south wales | 10 |
drug reaction | 10 |
medicine lists | 10 |
patients within | 10 |
myocardial dysfunction | 10 |
flow rate | 10 |
virus replication | 10 |
median delay | 10 |
actin cytoskeleton | 10 |
systems biology | 10 |
side effect | 10 |
prescription analysis | 10 |
may provide | 10 |
iv infection | 10 |
tibial nerve | 10 |
inappropriate medications | 10 |
missense mutation | 10 |
cross sectional | 10 |
rotational movement | 9 |
health status | 9 |
acute circulatory | 9 |
compared using | 9 |
significant proportion | 9 |
currently available | 9 |
basic reproduction | 9 |
certain number | 9 |
last decade | 9 |
rare disease | 9 |
data demonstrate | 9 |
dna sequencing | 9 |
force generation | 9 |
mechanical power | 9 |
low level | 9 |
dosage adjustment | 9 |
hospital universitario | 9 |
infrared spectroscopy | 9 |
brain damage | 9 |
nerve involvement | 9 |
nerve biopsies | 9 |
cryptosporidium parvum | 9 |
respiratory insufficiency | 9 |
bl mice | 9 |
metabolic pathways | 9 |
isotype igg | 9 |
identified using | 9 |
bacterial resistance | 9 |
cell walls | 9 |
hcv core | 9 |
lesser extent | 9 |
two consecutive | 9 |
defined according | 9 |
surgical procedures | 9 |
missing data | 9 |
kg month | 9 |
bilayer membranes | 9 |
veterinary expertise | 9 |
past history | 9 |
pcr products | 9 |
nursing homes | 9 |
tnf alpha | 9 |
genetic testing | 9 |
poor neurological | 9 |
deterministic continuous | 9 |
may play | 9 |
umr cnrs | 9 |
two independent | 9 |
effects model | 9 |
nasogastric tubes | 9 |
hospital length | 9 |
blood gas | 9 |
fecal samples | 9 |
cardiac output | 9 |
serum albumin | 9 |
functional outcome | 9 |
model based | 9 |
hcv ires | 9 |
age range | 9 |
rna transcript | 9 |
photosynthetic apparatus | 9 |
nasal oxygen | 9 |
veterinary services | 9 |
imaging techniques | 9 |
chest physiotherapy | 9 |
pearson correlation | 9 |
short time | 9 |
different proteins | 9 |
autonomic symptoms | 9 |
sirna antisense | 9 |
kv channels | 9 |
planar lipid | 9 |
organ donation | 9 |
method using | 9 |
molecule force | 9 |
membrane fluidity | 9 |
outcome indicators | 9 |
general condition | 9 |
supported lipid | 9 |
many studies | 9 |
biological activity | 9 |
folding process | 9 |
differential scanning | 9 |
infections due | 9 |
disc diffusion | 9 |
hemolytic anemia | 9 |
multiple organ | 9 |
electric field | 9 |
chlormethine gel | 9 |
coma scale | 9 |
modi ed | 9 |
cmv reactivation | 9 |
bacterial species | 9 |
remote system | 9 |
model membrane | 9 |
essential role | 9 |
mri showed | 9 |
lung ultrasound | 9 |
vitro model | 9 |
statistical analyses | 9 |
patient underwent | 9 |
well established | 9 |
poems syndrome | 9 |
efflux pumps | 9 |
group versus | 9 |
longer duration | 9 |
temporal resolution | 9 |
different levels | 9 |
dynamics simulation | 9 |
clinical evaluation | 9 |
genomic dna | 9 |
nerve roots | 9 |
previously published | 9 |
every weeks | 9 |
protein structures | 9 |
large cohort | 9 |
therapeutic agents | 9 |
intubated patients | 9 |
fluorescence anisotropy | 9 |
studies suggest | 9 |
drug market | 9 |
gestational age | 9 |
dimensional structure | 9 |
day pos | 9 |
vascular cause | 9 |
reference range | 9 |
blood mononuclear | 9 |
ascertained cases | 9 |
aux antibiotiques | 9 |
medication list | 9 |
acute exacerbations | 9 |
may serve | 9 |
dna molecule | 9 |
acute coronary | 9 |
suspected infection | 9 |
ombitasvir paritaprevir | 9 |
reference center | 9 |
descriptive statistics | 9 |
hemodynamic parameters | 9 |
maintenance treatment | 9 |
manuscript service | 9 |
enzyme activity | 9 |
studied patients | 9 |
specialized advice | 9 |
nosocomial pneumonia | 9 |
nan doi | 9 |
klebsiella spp | 9 |
lymph node | 9 |
monoclonal antibody | 9 |
patients starting | 9 |
structured interviews | 9 |
mg every | 9 |
young adults | 9 |
death rate | 9 |
three main | 9 |
prospective multicenter | 9 |
medical oncology | 9 |
enzymatic activity | 9 |
underlying cause | 9 |
csa ratio | 9 |
mpzs del | 9 |
systolic blood | 9 |
working group | 9 |
nutritional support | 9 |
paritaprevir ritonavir | 9 |
early identification | 9 |
positive blood | 9 |
structure prediction | 9 |
urban hierarchy | 9 |
dna sequences | 9 |
high fat | 9 |
related adverse | 9 |
cell activation | 9 |
helicobacter pylori | 9 |
clinical situations | 9 |
received antibiotics | 9 |
growth hormone | 9 |
first months | 9 |
second line | 9 |
cancer research | 9 |
detection rate | 9 |
local guidelines | 9 |
care system | 9 |
time consuming | 9 |
national hospital | 9 |
positive results | 9 |
medication changes | 9 |
acute stroke | 9 |
drug administration | 9 |
increasing number | 9 |
stochastic discrete | 9 |
water interface | 9 |
genetically confirmed | 9 |
inflammatory bowel | 9 |
three major | 9 |
beneficial effects | 9 |
muscle action | 9 |
amoxicillin clavulanic | 9 |
positive end | 9 |
aspiration pneumonia | 9 |
vice versa | 9 |
relatively low | 9 |
major role | 9 |
amyloid deposits | 9 |
extracellular matrix | 9 |
herd immunity | 9 |
middle ear | 9 |
also associated | 9 |
national council | 9 |
biological data | 9 |
endotracheal intubation | 9 |
patient management | 9 |
mean serum | 9 |
csf protein | 9 |
health problems | 9 |
useful tool | 9 |
amyloid deposition | 9 |
different methods | 9 |
quality assurance | 9 |
second group | 9 |
extracorporeal life | 9 |
correlation coefficient | 9 |
sickle cell | 9 |
potential clinical | 9 |
main risk | 9 |
give rise | 9 |
clinical information | 9 |
amyloid polyneuropathy | 9 |
resistant gram | 9 |
clinical criteria | 9 |
protocol group | 9 |
decompressive craniectomy | 9 |
different clinical | 9 |
virological failure | 9 |
treatment discontinuation | 9 |
plant gmos | 9 |
critical role | 9 |
chronic liver | 9 |
model using | 9 |
clinical research | 9 |
oral route | 9 |
higher rate | 9 |
treatment failure | 9 |
transgenic mice | 9 |
chemosensory changes | 9 |
severe bronchiolitis | 9 |
contact rate | 9 |
last year | 9 |
dimer formation | 9 |
multidisciplinary approach | 9 |
root ganglion | 9 |
case study | 9 |
four groups | 9 |
ko mice | 9 |
pump inhibitors | 9 |
dans un | 9 |
au cours | 9 |
enterococcus spp | 9 |
three weeks | 9 |
macrophage recruitment | 9 |
hospital pharmacist | 9 |
special interest | 9 |
survival rate | 9 |
genetic inheritance | 9 |
usual care | 9 |
hematologic malignancies | 9 |
vibration sense | 9 |
mg bid | 9 |
data protection | 9 |
gene encoding | 9 |
living cell | 9 |
resistance rate | 9 |
ibn rochd | 9 |
base pairing | 9 |
like structures | 9 |
spatial localisation | 9 |
transport effect | 9 |
natural history | 9 |
observation period | 9 |
ph values | 9 |
pulmonary arterial | 9 |
dynamical properties | 9 |
genomic rna | 9 |
european union | 9 |
glucose levels | 9 |
health issues | 9 |
ray diffraction | 9 |
infection control | 9 |
high degree | 9 |
factors independently | 9 |
diffusion model | 9 |
core antigen | 9 |
severe forms | 9 |
miller fisher | 9 |
common antibiotics | 9 |
see methods | 9 |
gene panel | 9 |
old calves | 9 |
therapeutic options | 9 |
male gender | 9 |
lunacy act | 9 |
skin temperature | 9 |
tested positive | 9 |
four times | 9 |
medical prescription | 9 |
taste loss | 9 |
initial state | 9 |
le kremlin | 8 |
secondary prevention | 8 |
axonal gbs | 8 |
sensory motor | 8 |
effective reproductive | 8 |
patients respectively | 8 |
good use | 8 |
south africa | 8 |
pain management | 8 |
reported changes | 8 |
chylous ascites | 8 |
also significantly | 8 |
protein function | 8 |
square test | 8 |
th percentile | 8 |
different cell | 8 |
selected articles | 8 |
scanning calorimetry | 8 |
matched controls | 8 |
sequence analysis | 8 |
rural areas | 8 |
clinical cure | 8 |
phone data | 8 |
ccru admissions | 8 |
fluid resuscitation | 8 |
therapeutic approaches | 8 |
three groups | 8 |
patients discharged | 8 |
stranded dna | 8 |
high throughput | 8 |
care facilities | 8 |
psychiatric wards | 8 |
conduction blocks | 8 |
pharmacy student | 8 |
drug interaction | 8 |
phase i | 8 |
time evolution | 8 |
reconciliation process | 8 |
population size | 8 |
major public | 8 |
resistance phenotypes | 8 |
antiplatelet therapy | 8 |
two times | 8 |
epidemic situation | 8 |
clinical findings | 8 |
natural killer | 8 |
transition region | 8 |
also reported | 8 |
studies reported | 8 |
data available | 8 |
potential impact | 8 |
carbon dioxide | 8 |
may occur | 8 |
limb weakness | 8 |
grand est | 8 |
french icus | 8 |
april th | 8 |
cumulated number | 8 |
site infection | 8 |
autonomic function | 8 |
bed medical | 8 |
findings may | 8 |
two components | 8 |
dissociation constant | 8 |
chi square | 8 |
currently used | 8 |
cryptosporidium infection | 8 |
serial interval | 8 |
rational use | 8 |
protein complex | 8 |
random effects | 8 |
since may | 8 |
th year | 8 |
right ventricular | 8 |
type iii | 8 |
preventive medicine | 8 |
cmt disease | 8 |
les prisons | 8 |
another study | 8 |
local trends | 8 |
april st | 8 |
rv failure | 8 |
cognitive function | 8 |
drug design | 8 |
real life | 8 |
nerve society | 8 |
structural studies | 8 |
school children | 8 |
valproate concentrations | 8 |
muscle mass | 8 |
severe brain | 8 |
also identified | 8 |
transplant patients | 8 |
tertiary structure | 8 |
perfect base | 8 |
anticancer drugs | 8 |
tirf microscopy | 8 |
reduced susceptibility | 8 |
ucb pharma | 8 |
cx ko | 8 |
human health | 8 |
temperature dependence | 8 |
lateral resolution | 8 |
thylakoid membranes | 8 |
start stopp | 8 |
months period | 8 |
ulnar nerves | 8 |
hcv subgenomic | 8 |
amyloid aggregation | 8 |
somatic cells | 8 |
low energy | 8 |
diastolic dysfunction | 8 |
fluorescence resonance | 8 |
targeted therapies | 8 |
dispensing data | 8 |
glomerular filtration | 8 |
paramount importance | 8 |
patients completed | 8 |
home medication | 8 |
distal weakness | 8 |
much less | 8 |
retrospectively reviewed | 8 |
generation cephalosporins | 8 |
major problem | 8 |
zoonotic transmission | 8 |
cell wall | 8 |
epidemiological data | 8 |
disability scale | 8 |
research centre | 8 |
many patients | 8 |
oxygen concentrator | 8 |
months prior | 8 |
fluorescence emission | 8 |
investigated using | 8 |
mean length | 8 |
pathogenic variants | 8 |
care setting | 8 |
multivariate logistic | 8 |
much lower | 8 |
aromatic residues | 8 |
gel phase | 8 |
also provide | 8 |
sensory axonal | 8 |
invasive fungal | 8 |
randomized trial | 8 |
cardiovascular diseases | 8 |
treatment initiation | 8 |
school closure | 8 |
potential therapeutic | 8 |
physiological ph | 8 |
study suggests | 8 |
aureus strains | 8 |
first weeks | 8 |
making use | 8 |
muscle fatigue | 8 |
hospital pharmacies | 8 |
selective pressure | 8 |
orf sequences | 8 |
length dependent | 8 |
developed countries | 8 |
early sepsis | 8 |
associated diarrhea | 8 |
fr annals | 8 |
population mobility | 8 |
negative rods | 8 |
daily clinical | 8 |
computer technology | 8 |
ill cancer | 8 |
around one | 8 |
older people | 8 |
rare diseases | 8 |
antibiotic regimen | 8 |
low temperature | 8 |
available data | 8 |
patients followed | 8 |
enterococcus faecium | 8 |
medication management | 8 |
multicenter cohort | 8 |
axonal polyneuropathy | 8 |
daily living | 8 |
gm gd | 8 |
prescription forms | 8 |
making process | 8 |
mechanical ventilator | 8 |
lipid peroxidation | 8 |
professional practices | 8 |
donor screening | 8 |
differed significantly | 8 |
rate limiting | 8 |
different stages | 8 |
time resolution | 8 |
psychotropic drugs | 8 |
hospital center | 8 |
first case | 8 |
public transportation | 8 |
predictive medicine | 8 |
experimental studies | 8 |
small molecules | 8 |
general practice | 8 |
medical team | 8 |
glass transition | 8 |
free survival | 8 |
mean total | 8 |
structural data | 8 |
first report | 8 |
experiments show | 8 |
fourier transform | 8 |
new insights | 8 |
recent advances | 8 |
reaction center | 8 |
obtained results | 8 |
phase ii | 8 |
farm animal | 8 |
specific treatment | 8 |
three years | 8 |
scientific meetings | 8 |
acute onset | 8 |
na ions | 8 |
kg ivig | 8 |
buffered saline | 8 |
nerve enlargement | 8 |
frequently observed | 8 |
enterobacter cloacae | 8 |
cho cells | 8 |
healthcare costs | 8 |
daily practice | 8 |
bacterial pneumonia | 8 |
versus cmd | 8 |
bloodstream infection | 8 |
time period | 8 |
neurological diseases | 8 |
electrical stimulation | 8 |
deep tendon | 8 |
protein synthesis | 8 |
current practice | 8 |
per cent | 8 |
motor nerves | 8 |
fluorescent probes | 8 |
serum levels | 8 |
per month | 8 |
severe traumatic | 8 |
interquartile range | 8 |
medical conditions | 8 |
different concentrations | 8 |
different species | 8 |
membrane fusion | 8 |
cases tested | 8 |
powerful tool | 8 |
time pcr | 8 |
energy landscape | 8 |
biological sciences | 8 |
myelinating schwann | 8 |
high case | 8 |
good correlation | 8 |
high compliance | 8 |
clinical pharmacology | 8 |
randomly selected | 8 |
anabolic steroids | 8 |
information leaflets | 8 |
novel method | 8 |
molecular medicine | 8 |
organ support | 8 |
chemical modifications | 8 |
oral suspension | 8 |
motor latency | 8 |
study focused | 8 |
previous study | 8 |
abnormal swt | 8 |
recently developed | 8 |
stimulated emission | 8 |
whitney test | 8 |
bordetella pertussis | 8 |
lockdown strategies | 8 |
genetic diagnosis | 8 |
pulmonary infection | 8 |
hepatocellular carcinoma | 8 |
cholesterol levels | 8 |
antibiotic concentrations | 8 |
multivariable analysis | 8 |
hiv hcv | 8 |
synergy test | 8 |
mononuclear cells | 8 |
psychiatrie en | 8 |
abdominal effusion | 8 |
adult stem | 8 |
induced pulmonary | 8 |
less severe | 8 |
liquid crystalline | 8 |
na channels | 8 |
transfected cells | 8 |
delivery systems | 8 |
screening strategies | 8 |
transmission electron | 8 |
diagnosed cases | 8 |
potential interactions | 8 |
overall survival | 8 |
pulmonary tuberculosis | 8 |
imaging microscopy | 8 |
different ph | 8 |
study demonstrates | 8 |
large enough | 8 |
ventilatory support | 8 |
les mesures | 8 |
sheep blood | 8 |
plasma concentration | 8 |
chronic disease | 8 |
associated protein | 8 |
life threatening | 8 |
correlation coefficients | 8 |
assess whether | 8 |
pmp tg | 8 |
pharmacy activities | 8 |
low frequency | 8 |
antimicrobial activity | 8 |
congo red | 8 |
expert panel | 8 |
adhesion molecules | 8 |
muscular atrophy | 8 |
cmap amplitude | 8 |
orthostatic hypotension | 8 |
epidemic dynamics | 8 |
new tool | 8 |
care pathway | 8 |
previous reports | 8 |
dependent antibodies | 8 |
igg antibody | 8 |
pediatric patients | 8 |
sural nerves | 8 |
coli isolates | 8 |
low levels | 8 |
methods section | 8 |
outgoing traffic | 8 |
high adherence | 8 |
neurodegenerative diseases | 8 |
colorectal cancer | 8 |
des soins | 8 |
max planck | 8 |
norway please | 8 |
negative staphylococci | 8 |
ecmo support | 8 |
compound muscle | 8 |
dendritic cells | 8 |
frequently prescribed | 8 |
heat shock | 8 |
lymph nodes | 8 |
rein registry | 8 |
synchrotron radiation | 8 |
exact test | 8 |
tunisia correspondence | 8 |
electrical activity | 8 |
fluorescence techniques | 8 |
governmental indicator | 8 |
alzheimer disease | 8 |
dna ejection | 8 |
interfering rna | 8 |
following injury | 8 |
highest level | 8 |
new drug | 8 |
onset cases | 8 |
average case | 8 |
two percent | 8 |
nucleotide sequences | 8 |
asthma control | 8 |
high number | 8 |
conventional methods | 8 |
treatment options | 8 |
also shown | 8 |
subgroup analysis | 8 |
producing strains | 8 |
low risk | 8 |
des cas | 8 |
total amount | 8 |
volume expansion | 8 |
first cases | 8 |
retrospective monocentric | 8 |
ii diabetes | 8 |
secondary endpoints | 8 |
first episode | 8 |
diabetic ketoacidosis | 8 |
fluid balance | 8 |
mainly due | 8 |
incidence data | 8 |
home care | 8 |
upper limb | 8 |
opportunistic infections | 8 |
high proportion | 8 |
results one | 8 |
patients affected | 8 |
plasmid dna | 8 |
integral membrane | 8 |
neurological institute | 8 |
motor function | 8 |
biopsy specimens | 8 |
producing enterobacteriaceae | 7 |
metal ions | 7 |
symptomatic treatment | 7 |
neuropathy associated | 7 |
experimental evidence | 7 |
provides information | 7 |
high concentration | 7 |
introduction acute | 7 |
expiratory muscle | 7 |
dna strands | 7 |
cattle vets | 7 |
degenerative illnesses | 7 |
resistance mutations | 7 |
solitary confinement | 7 |
will need | 7 |
national health | 7 |
molecular diagnosis | 7 |
stroke patients | 7 |
morphological changes | 7 |
dna molecules | 7 |
phenotypic correlations | 7 |
approved indications | 7 |
network model | 7 |
rat model | 7 |
southern france | 7 |
positive cases | 7 |
factor associated | 7 |
antiretroviral drugs | 7 |
mrc score | 7 |
rate variability | 7 |
ethical committee | 7 |
coated tablets | 7 |
gas infection | 7 |
rsv patients | 7 |
particularly important | 7 |
national space | 7 |
germany purpose | 7 |
major risk | 7 |
different geographical | 7 |
prehospital setting | 7 |
lymphocyte count | 7 |
yong loo | 7 |
postoperative infections | 7 |
proton transfer | 7 |
patients fulfilling | 7 |
insulin therapy | 7 |
drugs prescribed | 7 |
decreased significantly | 7 |
may represent | 7 |
large population | 7 |
patient compliance | 7 |
psychological consult | 7 |
serum vancomycin | 7 |
will discuss | 7 |
different sources | 7 |
first wave | 7 |
chaperone activity | 7 |
label use | 7 |
frequent complication | 7 |
lin school | 7 |
strongly associated | 7 |
national agency | 7 |
statistically different | 7 |
microscopy techniques | 7 |
molecular biophysics | 7 |
loo lin | 7 |
biological processes | 7 |
muscle fibres | 7 |
persistent aki | 7 |
educational program | 7 |
different forms | 7 |
training program | 7 |
myelinated fibers | 7 |
sodium channels | 7 |
undocumented medication | 7 |
creative commons | 7 |
lv diastolic | 7 |
motion analysis | 7 |